This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
“But we are glad to see the situation for innovative drugs in Asian markets improving, especially in mainland China and South Korea, where policies, societies and regulations are actively promoting innovation. “At At the same time, lots of people with experience at multinational pharmaceuticalcompanies have chosen to return home.
In a bid to resolve both physical and financial restrictions inhibiting equitable access to quality medicines, the Jan Aushadhi scheme was launched in 2008 and envisaged the setting up of dedicated Janaushadhi Kendras to provide quality generic medicines at capped prices for the general public.
For many years, the pharmaceutical industry has been accused of overlooking this patient population by instead targeting investments toward more prevalent indications. First established in 2008, Rare Disease Day is observed every 28 February, with events set up across more than 100 countries in 2023 to unite the world in raising awareness.
The world’s biggest pharmaceuticalcompany Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. ” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.” So what’s driving the growth?
What are the top three trends impacting the cardiovascular drugdevelopment space today? Beyond clinical trials, what other challenges are impacting pharmaceuticalcompanies today? You see very few cardiovascular companies as a startup biotech, and there are reasons for that.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.
Several drugdevelopment trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. The number of requirements in the revised Annex 1 has been significantly expanded from the original 2008 version and will come into force on 25 August 2023.
It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals. As understanding of biological systems has forged ahead, pharmaceuticalcompanies have made increasing use of biotechnology in discovering and manufacturing new medicines.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content